P&G Increases Stake In Regeneron; Vertex Rides On Novartis Endorsement
Procter & Gamble's stake in Regeneron will increase to 16% with the purchase of an additional 573,630 Regeneron shares.
You may also be interested in...
Procter & Gamble CEO-elect A.G. Lafley will inherit the task of settling the appropriate size for P&G's investment in the pharmaceutical business.
Geltex' bile acid sequestrant Welchol (colesevelam) reduces LDL cholesterol by 48% in combination with Warner-Lambert/Pfizer's Lipitor (atorvastatin).
Novartis has augmented its U.S. research profile with a long-term drug discovery deal with Cambridge, Mass.-based Vertex Pharmaceuticals.